Azenta Q3 revenue flat, misses estimates; EPS rises

Azenta

05/08/2025 11:45

Overview

Azenta Q3 revenue flat yr/yr at $144 mln, missing analysts' expectations

Non-GAAP diluted EPS from continuing ops rises to $0.19

Adjusted EBITDA increases to $18 mln, margin rises 260 basis points to 12.3%

Outlook

Azenta reiterates fiscal 2025 organic revenue growth of 3% to 5%

Company expects adjusted EBITDA margin to expand by 300 bps in fiscal 2025

Result Drivers

MULTIOMICS GROWTH - Revenue increased 4% driven by Next Generation Sequencing, partially offset by declines in Sanger Sequencing and Gene Synthesis

SAMPLE MANAGEMENT DECLINE - Revenue decreased 4% due to lower sales in Automated Stores and Cryogenic Systems, despite gains in Sample Storage and Clinical Biostores

MARGIN EXPANSION - Gross margin improved by 170 basis points due to favorable sales mix and cost execution

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$144 mln
$149.40 mln (8 Analysts)
Q3 Adjusted EBITDA
$18 mln
Q3 Gross Margin
47.1%
Q3 Adjusted EBITDA Margin
12.3%
Q3 Operating Income
-$700,000


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Azenta Inc is $32.50, about 0.3% above its August 4 closing price of $32.41

The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release: ID:nPn2g4HjLa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)